Compare Novavax Inc (NVAX) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novavax Inc trades at $11.1 (market cap $1.82B), while Direxion Daily TSLA Bull 2X Shares trades at $10.3 (market cap $3.97B). The key difference: Direxion Daily TSLA Bull 2X Shares is far larger — about 2.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| NVAX | TSLL | |
|---|---|---|
Market Cap | $1.82B | $3.97B |
Volume | 6,198,505 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $12.56 | $23.03 |
52-Week Low | $6.22 | $6.74 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's performance, with a rally noted ahead of the Cybercab event. The ETF's structure amplifies daily returns, making it highly volatile and dependent on Tesla's stock movements.
The outlook for TSLL is tied directly to Tesla's stock volatility and news flow. Investment opportunities exist for traders seeking leveraged exposure to Tesla's upside, but risks include significant volatility decay and the potential for amplified losses. Investors should be cautious of the ETF's daily reset mechanism, which can lead to underperformance over time compared to holding Tesla stock directly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
